Revolution Medicines, Inc.
RVMD
DELAYED 1 MONTH
9 insider filings · Latest: May 26, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 3,121 | $153.99 | $480.6K | 54,400(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 36,000 | $101.23 | $3.6M | 64,424(I) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,121 | $33.62 | 106,109(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Grant/Award | 128,600 | $102.02 | 128,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Margaret A HornChief Operating Officer | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Jeff CisliniGeneral Counsel | Grant/Award | 32,500 | $102.02 | 32,500(D) | View → |
| Mar 1, 2026 | Mar 4 2:07 AM | Jack AndersChief Financial Officer | Grant/Award | 45,400 | $102.02 | 45,400(D) | View → |